Nine Chapters Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nine Chapters Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-4,300	Closed	-$515K	–	982
2015 Q2	$515K	Sell	4,300 -700	-14%	-$83.7K	0.04%	563
2015 Q1	$522K	Buy	+5,000	New	+$507K	0.04%	592
2013 Q3	–	Sell	-9,800	Closed	-$304K	–	740
2013 Q2	$304K	Buy	+9,800	New	+$261K	0.05%	452

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Nine Chapters Capital Management's ALNY Position: Q3 2015 in Review

Nine Chapters Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2015, closing a stake of 4,300 shares — an estimated $515K sold.

Nine Chapters Capital Management first reported a position in ALNY in Q2 2013 and held it in 3 quarters. The position peaked at $522K in Q1 2015. 258 funds tracked by Wall St. Rank hold ALNY as of Q3 2015.

Nine Chapters Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 4,300 Alnylam Pharmaceuticals shares in Q3 2015, an estimated $515K.
Nine Chapters Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Nine Chapters Capital Management's Alnylam Pharmaceuticals position peaked at $522K in Q1 2015.
258 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2015.

Based on Nine Chapters Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.